• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

From fixed activities to personalized treatments in radionuclide therapy: lost in translation?

作者信息

Flux G D, Sjogreen Gleisner K, Chiesa C, Lassmann M, Chouin N, Gear J, Bardiès M, Walrand S, Bacher K, Eberlein U, Ljungberg M, Strigari L, Visser E, Konijnenberg M W

机构信息

Joint Department of Physics, Royal Marsden Hospital & Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.

Department of Medical Radiation Physics, Lund University, Lund, Sweden.

出版信息

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):152-154. doi: 10.1007/s00259-017-3859-1. Epub 2017 Oct 27.

DOI:10.1007/s00259-017-3859-1
PMID:29080096
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5700228/
Abstract
摘要

相似文献

1
From fixed activities to personalized treatments in radionuclide therapy: lost in translation?从放射性核素治疗中的固定活动到个性化治疗：翻译中迷失了吗？
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):152-154. doi: 10.1007/s00259-017-3859-1. Epub 2017 Oct 27.
2
Radionuclide Therapies: An Overview of Applications.放射性核素治疗：应用概述。
Radiol Technol. 2021 Jul;92(6):595-614.
3
'Image and treat': an individualized approach to urological tumors.“图像引导下的治疗”：一种针对泌尿系统肿瘤的个体化方法。
Curr Opin Oncol. 2010 May;22(3):274-80. doi: 10.1097/CCO.0b013e3283373d5c.
4
Harnessing Cu/Cu for a theranostic approach to pretargeted radioimmunotherapy.利用 Cu/Cu 实现前靶向放射性免疫治疗的治疗策略。
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28316-28327. doi: 10.1073/pnas.2009960117. Epub 2020 Oct 26.
5
Pretargeting: A Path Forward for Radioimmunotherapy.前靶向：放射免疫治疗的一个前进方向。
J Nucl Med. 2022 Sep;63(9):1302-1315. doi: 10.2967/jnumed.121.262186.
6
Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges.放射性免疫治疗用于递送细胞毒性放射性同位素：现状与挑战。
Expert Opin Drug Deliv. 2018 Feb;15(2):185-196. doi: 10.1080/17425247.2018.1378180. Epub 2017 Sep 12.
7
Radionuclide Therapies in Molecular Imaging and Precision Medicine.分子成像与精准医学中的放射性核素疗法
PET Clin. 2017 Jan;12(1):93-103. doi: 10.1016/j.cpet.2016.08.006. Epub 2016 Sep 19.
8
Glypican-3 targeted delivery of Zr and Y as a theranostic radionuclide platform for hepatocellular carcinoma.基于 Glypican-3 的Zr 和 Y 放射性核素靶向递呈平台用于肝细胞癌的诊断与治疗。
Sci Rep. 2021 Feb 12;11(1):3731. doi: 10.1038/s41598-021-82172-w.
9
Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors.儿科肿瘤的诊断治疗学方面和放射免疫治疗
Int J Mol Sci. 2020 May 28;21(11):3849. doi: 10.3390/ijms21113849.
10
Radioimmunotherapy for high-grade glioma.放射性免疫治疗高级别胶质瘤。
Immunotherapy. 2013 Jun;5(6):647-59. doi: 10.2217/imt.13.43.

引用本文的文献

1
A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [Lu]Lu-DOTATATE to favor its use in clinical practice.比较个体化放射性配体治疗（RLT）中使用 [Lu]Lu-DOTATATE 治疗神经内分泌肿瘤（NEN）患者的简化方案，以促进其在临床实践中的应用。
Eur J Nucl Med Mol Imaging. 2023 May;50(6):1753-1764. doi: 10.1007/s00259-023-06112-8. Epub 2023 Jan 23.
2
Individualization of Radionuclide Therapies: Challenges and Prospects.放射性核素治疗的个体化：挑战与前景
Cancers (Basel). 2022 Jul 14;14(14):3418. doi: 10.3390/cancers14143418.
3
Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation.人工智能在核医学和分子影像中的应用：临床转化的现状和未来展望综述。
Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4452-4463. doi: 10.1007/s00259-022-05891-w. Epub 2022 Jul 9.
4
Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with Lu-PSMA I&T therapy.应用机器学习技术在 Lu-PSMA I&T 治疗的晚期前列腺癌男性患者的治疗前预测剂量学评估中的应用。
Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4064-4072. doi: 10.1007/s00259-022-05883-w. Epub 2022 Jun 30.
5
The internal dosimetry user group position statement on molecular radiotherapy.内部剂量学用户组关于分子放射治疗的立场声明。
Br J Radiol. 2021 Oct 1;94(1126):20210547. doi: 10.1259/bjr.20210547. Epub 2021 Aug 25.
6
Clinical implementation of PLANET® Dose for dosimetric assessment after [Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0.[镥]镥-多他肽（[Lu]Lu-DOTA-TATE）后用于剂量学评估的PLANET®剂量的临床应用：与剂量学工具包（Dosimetry Toolkit®）和OLINDA/EXM® V1.0的比较
EJNMMI Res. 2021 Jan 4;11(1):1. doi: 10.1186/s13550-020-00737-8.
7
Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy.分子放射治疗中肿瘤吸收剂量计算的不确定性分析
EJNMMI Phys. 2020 Oct 12;7(1):63. doi: 10.1186/s40658-020-00328-5.
8
Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management.肽受体放射性核素治疗后的剂量测定：治疗后研究数量减少对吸收剂量计算和患者管理的影响。
EJNMMI Phys. 2020 Jan 23;7(1):5. doi: 10.1186/s40658-020-0273-8.
9
Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.研究 PSMA 靶向放射性配体治疗的疗效与细胞 PSMA 水平和肿瘤内 PSMA 异质性的关系。
Clin Cancer Res. 2020 Jun 15;26(12):2946-2955. doi: 10.1158/1078-0432.CCR-19-1485. Epub 2020 Jan 13.
10
Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches.个体化放射性核素治疗、分子放射治疗及诊疗一体化方法的概念展望。
Nucl Med Mol Imaging. 2019 Jun;53(3):167-171. doi: 10.1007/s13139-019-00586-x. Epub 2019 Jan 29.

本文引用的文献

1
Dosimetry in clinical radionuclide therapy: the devil is in the detail.临床放射性核素治疗中的剂量测定：细节决定成败。
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2137-9. doi: 10.1007/s00259-017-3820-3. Epub 2017 Sep 10.
2
The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy.肿瘤核医学治疗中治疗优化与放射性药物固定活度剂量学登记之间的冲突。
Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1783-1786. doi: 10.1007/s00259-017-3707-3. Epub 2017 May 24.
3
Individualised Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.基于肾脏剂量测定的神经内分泌肿瘤个体化卢-多他赛治疗。
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1480-1489. doi: 10.1007/s00259-017-3678-4. Epub 2017 Mar 22.
4
Whole-remnant and maximum-voxel SPECT/CT dosimetry in I-NaI treatments of differentiated thyroid cancer.分化型甲状腺癌碘-碘化钠治疗中全残留和最大体素SPECT/CT剂量测定法
Med Phys. 2016 Oct;43(10):5279-5287. doi: 10.1118/1.4961742.
5
High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with Y-loaded glass microsphere radioembolization.基于大颗粒白蛋白的肿瘤剂量对接受钇-负载玻璃微球放射性栓塞治疗的肝细胞癌患者的反应和总生存期有重大影响。
Liver Int. 2017 Jan;37(1):101-110. doi: 10.1111/liv.13220. Epub 2016 Sep 23.
6
Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.使用（177）Lu-DOTA-奥曲肽进行肽受体放射性核素治疗后的肾毒性。
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1802-11. doi: 10.1007/s00259-016-3382-9. Epub 2016 May 10.
7
Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.通过¹²⁴I PET/CT评估接受放射性碘治疗的分化型甲状腺癌患者的剂量-反应关系
J Nucl Med. 2016 Jul;57(7):1027-32. doi: 10.2967/jnumed.115.168799. Epub 2016 Feb 25.
8
Uncertainty propagation for SPECT/CT-based renal dosimetry in (177)Lu peptide receptor radionuclide therapy.基于SPECT/CT的（177）镥肽受体放射性核素治疗中肾脏剂量测定的不确定性传播
Phys Med Biol. 2015 Nov 7;60(21):8329-46. doi: 10.1088/0031-9155/60/21/8329. Epub 2015 Oct 12.
9
Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.使用¹⁷⁷Lu-DOTATATE的肽受体放射性核素治疗对胰腺神经内分泌肿瘤的剂量反应。
J Nucl Med. 2015 Feb;56(2):177-82. doi: 10.2967/jnumed.114.148437. Epub 2015 Jan 15.
10
The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.分子放疗临床实践中内照射剂量学应用的证据基础。
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1976-88. doi: 10.1007/s00259-014-2824-5. Epub 2014 Jun 11.